Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma - pathological development and restitution.
Department of Oncology, Central Hospital , Karlstad , Sweden.
Karin
K
Hallén
Per
P
Sangfelt
Thomas
T
Nilsson
Hans
H
Nordgren
Alkwin
A
Wanders
Daniel
D
Molin
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001653:Bile Ducts, Intrahepatic / Q000473:pathology; D001761:Bleomycin / Q000008:administration & dosage; D002352:Carrier Proteins / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007565:Jaundice / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D000069283:Rituximab; D013577:Syndrome; D014750:Vincristine / Q000008:administration & dosage
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D002352:Carrier Proteins; C429222:goblet cell silencer inhibitor; D001761:Bleomycin; D011344:Procarbazine; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone